Woodline Partners LP Xenon Pharmaceuticals Inc. Transaction History

Woodline Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $1.52 Million - $2.46 Million	53,002 Added 36.95%	196,453 $9.05 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $5.02 Million - $5.84 Million	-146,949 Reduced 50.6%	143,451 $4.9 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $4.52 Million - $5.64 Million	-129,629 Reduced 30.86%	290,400 $11.2 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $4.07 Million - $4.91 Million	121,589 Added 40.74%	420,029 $15 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $3.5 Million - $4.18 Million	-105,919 Reduced 26.19%	298,440 $11.8 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $5.4 Million - $6.99 Million	175,431 Added 76.63%	404,359 $14.6 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $5.82 Million - $8.05 Million	228,928 New	228,928 $6.96 Million
Q4 2021 Feb 14, 2022	SELL	$15.6 - $35.4 $3.12 Million - $7.08 Million	-199,984 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $2.97 Million - $3.89 Million	199,984 New	199,984 $3.06 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.